SK Bioscience Receives MFDS Approval for Phase 3 Clinical Trial of COVID-19 Vaccine
[Asia Economy Reporter Ji Yeon-jin] SK Bioscience announced on the 10th that it has received approval from the Ministry of Food and Drug Safety for the Phase 3 clinical trial plan (IND) of the COVID-19 vaccine (GBP510).
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Living the Homebody Dream? "I Was Shocked by My Spending" How to Cut Costs to 5,000 Won for Essentials [The Principles of Benefits]
- Is It Really Like an Illness? "I Can't Wait to Go Again"—Over 1 Million Visited in Q1, Now 'Busanbyeong' Takes Hold [K-Holic]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
This clinical trial will be conducted as a multicenter, parallel-comparison, observer-blinded, active-controlled, randomized study to evaluate the immunogenicity and safety of the 'SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510)' in adults aged 18 and older.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
